



COMPLICATIONS AND MANAGEMENT OF ALZHEIMER'S DISEASE

¹Pawar Sonali Baban, ²Bole Sandesh Sachhidanand, ³Pawale Saurbh Nandkumar, ⁴Nath Rakesh Sanjay,

¹Assistant Professor, ²Assistant Professor, ³Assistant Professor, ⁴UG Scholar, Matoshri Miratai Aher college of Pharmacy, Karjule Harya, Tal- Parner, Dist- Ahmednagar, Maharashtra.

ABSTRACT

Alzheimer's disease (AD) is one in all the foremost necessary neurodegenerative disorders within the twenty first century for the regularly aging population. Despite associate increasing range of patients, there are solely few medication to treat the malady. Alzheimer disease (AD) is that the most typical explanation for dementedness that affects quite forty four million people worldwide. It's been detected that there's solely symptomatic treatments are on the market to treat AD, however no cure exists. It's a neurodegenerative malady characterized by Alois Alzheimer's in 1906, and neuro chronic diseases are one in all the foremost issues facing by the trendy health care system. It's a varied complicated malady that Pathology not clearly understood however it's usually characterized by vegetative cell harm, memory pathology, etc. pathological Hallmark issue for Alzheimer malady is deposition of amyloid- β ($A\beta$) Plaques round the neurons, neurofibrillary tangles, and a decrease in neurotransmitter concentration and a few alternative neurochemical dysregulation. Differing kinds of risk factors like aerophilic stress, Obesity, diabetes, cardiovascular disease, pollution, smoking, hyper cholesterolemia etc. have a really vital role within the development of AD and within the development of its preventive measures. Workout and biological process factors are shown as protecting Measures for it and facilitate in its hindrance. For the identification of it, we have a tendency to Use body fluid biomarkers and antilepton emission pictorial representation Etc. Currently, there are 2 standard pharmacotherapies exist for AD that is approved by Food and Drug Administration (FDA) are Respectively- acetyl-cholinesterase inhibitors- tacrine, donepezil, Rivastigmine, galantamine and N-methyl-D-aspartate salt Antagonist (NMDA)-memantine.

Keywords:- Alzheimer's, complications of Alzheimer's, management, treatment, Alzheimer Dementess, Alzheimer's malady.

INTRODUCTION

Because of the world rise in anticipation, the impact of chronic conditions related to age is growing. One amongst the Fore most difficult problems is dementedness, and five hundredth of dementedness cases area unit a results of Alzheimer's Illness. Alzheimer's illness (AD) is that the commonest explanation for dementedness and is clinically characterized by a Progression from personal memory issues to a slow general decline of psychological feature ¹. Alzheimer illness probably Contributes to sixty to seventieth of cases. Alternative forms of Dementia embody tube shaped structure dementia, Dementedness with Lewy bodies, And a gaggle of diseases that contribute to front to temporal dementedness. The Boundaries between Subtypes area unit faint and mixed forms typically co-exist ². Dementia will have an effect on an individual in numerous ways in which, and progression of the illness depends upon the Impact of the illness itself and also the person's temperament and state of health. Dementia may be divided in 3 stages.

Stages:

- **Early stage** – initial year or 2
- **Middle stage** – second to fourth or fifth years
- **Late stage** – fifth year and once

These periods area unit given as Associate in Nursing approximate guideline and not all persons with dementedness can Show identical symptoms ³. AD pathology presents a fancy interaction between many organic chemistry alterations, as well as changes in amyloid Precursor macromolecule metabolism, Phosphorylation of the letter of the alphabet macromolecule, aerophilic stress, Impaired energetics, mitochondrial pathology, inflammation, membrane macromolecule dysregulation and neurochemical Pathway Disruption ⁴. Most of those pathological options may be directly coupled to metabolic Abnormalities and it's currently clear that metabolic pathology is a crucial considers AD. Example, impaired cerebral aldohexose uptake happens decades before the Onset of psychological feature pathology Associate in Nursingd is an invariant feature of AD. The well-documented Neurotoxicity related to related to thought to participate in impaired neuronics energetics through Initiating a cascade of Pathological events; interaction between A β 42 and mitochondrial Enzymes results in enhanced unleash of reactive element Species (ROS), moving metastasis, The TCA cycle and mitochondrial respirator chain activity through the build up of Injurious intermediate metabolites within the within the medications for kind a pair of polygenic disorder (T2DM)have Favorable effects on Brain energy metabolism and supply a viable path for the invention And development of interventions For dementedness syndromes. Indeed, giant info studies reveal Associate in nursing association between many categories Of anti-diabetes medications and a lower risk of dementia.

Alois Alzheimer and Auguste D

The German medical specialist and neuropathologist Dr. Alois Alzheimer is attributable with Describing for the primary time a dementing condition that later became referred to as AD. In his Landmark 1906 conference lecture and a resulting 1907 article, Alzheimer delineate the Case of Auguste D, a 51-year-old lady with a 'peculiar sickliness of the cortex,' UN agency Had bestowed with progressive memory and language impairment, disorientation, behavioural Symptoms (hallucinations, delusions, paranoia), and psychosocial impairment.

Risk Factors for AD

- **Age:-** The a lot of people advance in age the upper is that the risk they'll develop Alzheimer sickliness. Most patients develop AD once the age of sixty five years previous. The danger of developing AD Reaches five hundredth for people on the far side age eighty five. As a result of a lot of and a lot of folks live longer lives This sickliness is turning into a significant concern. The age-specific incidence rates for Alzheimer sickliness demonstrate a doubling of incidence for concerning each six years of adscititious life, that indicates Associate in Nursing exponential increasing risk with increasing age. This exponential risk is fairly similar across studies, in spite of geographical region, although the underlying absolute incidence rate ¹¹.
- **Genetics of AD:** - The overwhelming majority of Alzheimer sickliness isn't genetically heritable though some genes could act as risk factors ¹². Genetically known styles of Alzheimer sickliness that typically has Associate in nursing onset before the age of sixty five, are known and account for zero. 1% of sickliness cases ¹³. This thinking is that there square measure sporadic/late onset and familial/early onset cases of Alzheimer sickliness.
- **Role of atmosphere for AD:-** many studies indicate a job for environmental effects on AD development. During a recent review Richard Mayeux and Yaakov Stern summarized the role of diet, activities, or sicklinesss that doubtless play a job within the onset of Alzheimer disease. Diabetes, high blood pressure, smoking, obesity, and dyslipidemia have all been found to increase risk still a history of brain trauma, vas sickliness, and vasculopathies ¹⁴.
- **Diabetes:** Insulin-degrading protein works as a Cleavage protein for hormone and amyloid β . In sort a pair of polygenic disease thanks to a decrease in hormone sign, Production of insulin-degrading protein ablated, and it results in results in and hyper-insulinemia¹⁵. Phosphorylation of letter of the alphabet proteins, and that they all show a central load for the pathologic process of Alzheimer

sickliness.

- **Hypertension:** it should elevate the danger of AD through reducing the barrier (BBB) tube-shaped structure integrity, which can result into the super molecule Extravasation in brain tissues and results in Accumulation of $A\beta$ ¹⁷.
- **Obesity:** fat is characterised by a chronic Moderate general inflammation, that results in a Brain inflammatory method and ab initio characterised by redoubled cytokines secretion it's a pro-inflammatory issue, and cytokines that square measure primarily concerned in it square measure neoplasm death issue alpha ($TNF\alpha$), interleukin-1beta ($IL-1\beta$), chemokine and interleukin-6 ($IL-6$)¹⁸. Oxidative stress: it's associated with aerobic harm of nucleic acids, protein, lipid, and carbohydrates by chemical reaction of those of those, There square measure many sources that square measure concerned within the production of reactive element species (ROS)²⁰
- **Physical Exercise:** it's studied that physical activity works as Associate in Nursing improvement issue for neurotrophic issues like brain-derived neurotrophic factor (BDNF) quantity, and their neuroprotective action provides a useful result in AD by rising psychological feature. Routine exercise additionally works as a conditioner for aerobic stress and reactive element species (ROS), through reducing ROS created super molecule harm, it provides a protecting effort in neurodegeneration and AD²¹, physical exertion additionally decreases the extent of neoplasm death issue alpha ($TNF-\alpha$), interleukin-1 alpha ($IL-1\alpha$) that results in decrease within the within the neuroinflammation of the brain and provides a marker for AD diagnosing, protective result in psychological feature or dementedness²². physical exertion induces IDE and NEP action By that that accumulation doesn't occur that is Hypothesized the foremost vital issue for Alzheimer's pathology.




Fig 1 :- physical activity and through it prevention of AD²⁴.

- **Nutritional Factor:** it's according that if we tend to take a diet that is extremely made in sterol, carbohydrates, and fats, results show a really prejudicious role in AD. Is found that if we tend to intake of dietary antioxidant however don't take additional antioxidant supplement. Insufficiency of vitamin B, B and B vitamin outcomes into the rise within the homocysteine level and homo-Cysteine will increase concentration associated with the AD As a neurolysin²³. Cerebro body fluid (CSF) Biomarkers: Amyloid- β and letter of the alphabet proteins deposition area unit thought of for AD pathology. Within the CSF low quantity of $A\beta$ and a better quantity of total letter of the alphabet and Phosphorylated letter of the alphabet (P-tau) proteins area unit supposed as a marker for AD identification.

❖ Risk Factors for LOAD

To minimize the likelihood of a future with a high proportion of individuals with AD, it's necessary to see that area unit the factors that influence this malady. In recent years, a big variety of epidemiologic studies associated with the definition of risk factors for AD are printed. Risk factors for LOAD area unit classified as status genes and environmental factors²⁵. LOAD encompasses a sturdy genetic element, namely, Apo lipoprotein E (ApoE), the foremost wide studied genetic risk issue for AD²⁶.

Genetic condition to LOAD

Apolipoprotein area unit a family of proteins concerned in super molecule physiological state, that bind and transport lipids through the liquid body substance and circulatory systems²⁷. It's been shown that ApoE contains a sturdy relationship with the pathologic process of LOAD²⁸. ApoE could be a conjugated protein of 299 amino acids and its structure varies looking on genetic polymorphisms. The 3 major ApoE isoforms take issue from one another by aminoalkanoic acid substitutions at positions 112 and 158 wherever the wild-type $\epsilon 3$ factor is Cys112 and Arg158, whereas the ApoE $\epsilon 2$ factor carries the Cys112 and Cys158 polymorphism, and also the and also the factor contains Arg112 and Arg158. A deficiency in ApoE may end up in modifications in its structure and performance [32], associate degree an alteration of the operate of ApoE leads to a rise of plasma levels of cholesterol and triglycerides²⁹. The ApoE $\epsilon 4$ factor is that the most vital genetic risk issue and it absolutely was in all probability 1st known as a risk issue for LOAD, by the format and acceleration of A β accumulation within the brain. There area unit varied studies that have replicated this association in numerous ethnic teams as well as African Americans³⁰, Latinos³¹, Asians³², and Caucasians^{33,34} moreover, a robust association has been reportable between the ApoE $\epsilon 4$ factor and dementedness because of AD pathology, however not with vascular dementia; but, another study made conflicting results showing that the ApoE $\epsilon 4$ factor contains a sturdy relationship with vascular dementedness through inveterately degenerating nerve tissue within the brain^{35,36}.

Metabolic and Non-genetic Risk Factors for LOAD:-

- **Hypercholesterolemia.** High body fluid and plasma sterol levels are recommended as risk factors for AD³⁷. Within the adult brain, primary sterol synthesis happens in astrocytes and in lesser proportion in neurons; sterol is transported into the brain by native high density lipoproteins (HDL). Lipoprotein (LDL) levels are elevated in vessel diseases and enlarged oxidization and nitration-related general modifications are ascertained in lipoprotein (oxLDL) in hypercholesteremia hypercholesteromia. In associate degree experimental cell-based study, sterol distribution among membrane is seen to own effects on APP metabolism, trafficking of APP, activities of β -, γ -, and α -secretases, and A β synthesis. The mechanism by that sterol deregulates A β metabolism has not nevertheless been elucidated, however many studies counsel that changes in sterol levels alter the plasma membrane because of impairment of lipid rafts, that are membrane micro domains targeted on macromolecule trafficking, signal transduction, and neurotransmission³⁹. The γ -secretase cleavage of APP, the ultimate step in A β amide production, happens in these cholesterol-rich lipid rafts³⁸. In a very recent study, it absolutely was recommended that inhibition of sterol synthesis, victimization AY9944, that blocks the ultimate step of sterol synthesis, reduces γ - secretase activity related to the generation of A β peptides. Moreover, low sterol levels increase α -secretase activity on APP⁴⁰, promoting neuroprotection by increasing levels of α APP fragments that are concerned in neurotrophic functions. In another study, it absolutely was according that plasma sterol levels in AD patients were elevated by concerning 100% compared to manage subjects, though' these levels are connected to the burden of ApoE⁴¹. The brain is capable of metabolizing sterol excess to oxysterols that are the merchandise of sterol oxidization. Several studies have according some oxysterols as well as 6-ch Hyperhomocysteinemia oleston-5 α -hydroperoxide, 7-oxocholesterol (7-ketocholesterol), 7 β -OHC (7 β -hydroxycholesterol), 7-dehydrocholesterol, 27-OHC (27-hydroxycholesterol), and 25-OHC (25-hydroxycholesterol)⁴². The intermediates 24-OHC and 27-OHC are ordinarily found within the plasma of patients with AD; therefore, these metabolites are terribly promising as biomarkers in AD patients. Enlarged levels of homocysteine depend upon many factors like age, genetics, lifestyle, and sex. The causes of this risk consider the population are multiple and embody each nongenetic and genetic mechanism. Deficiency of B, folate, and B complex is also chargeable for hypercholesteremia within the general population.⁴³ Pharmacological information show that homocysteine stimulates lipid accumulation, inflammatory processes,

and N-methyl-D-aspartate receptor (NMDA) activation^{44,46}.

- **Hypertension:-**

Many studies have joined high blood pressure to brain atrophy so the and also the generation of NFTs; therefore, associate degree association between high blood pressure and AD is conceivable⁴⁶. However, this association is complicated and differs with age. It's been shown that prime force per unit area in time of life is related to associate degree increased risk of AD⁴⁷.

- **Obesity:-**

Blubber may be a precursor condition for varied disorders, together with hypercholesteromia, upset, metabolic syndrome, and sort two diabetes (T2DM)⁴⁸. There area unit many studies linking blubber to increased psychological feature decline and AD risk and to central system inflammation through a rise in professional inflammatory cytokines. Studies in each human and animal model recommend that specific dietary constituents could also be vital in modulating AD risk⁴⁹. For instance, a diet wealthy in fatty acids is related to blubber and so with the next risk of AD. It absolutely was recently according that a high-fat diet causes harm like that ascertained in Alzheimer's pathology, like synergism of β -secretase process of APP, psychological feature impairment, and mitochondrial harm related to endocrine resistance⁵⁰. The influence of common free radicals and antioxidants in development of Alzheimer's Disease:-Oxygen, the foremost important and essential part, on the one Hand is obligatory for aerobic organisms however on the opposite will cause Aerophilous damages in cells. Aerophilous damages concern every style of cell and biological molecule, together with those most significant always, DNA, RNA, super molecule enzymes, unsaturated lipids, etc⁵¹. The said damages result in various disorders like Neurodegenerative, vessel, cancer, etc. Changes created for functioning in Alzheimer's sickliness the negative influence of chemical element is directly connected with molecules shaped by oxygen; specifically free radicals. These structures, which can be accurately characterized in next a part of the paper, embody various molecules that contain points of similarity like one or a lot of mismatched electrons. This cluster will embody extra, non-radical Aerophilous substances like peroxide H_2O_2 or nitrogen oxide N_2O_3 , which kind teams of reactive chemical element species, ROS and reactive gas species, RNA⁵². Free radicals area unit generated throughout diseases and treatment. On the opposite hand, factors like alcohol or cigarettes, that generate Tremendous of the harmful molecules, is avoided. Significant issues area unit connected with tobacco smoke. A number of the parts will turn out every style of atom, resulting in Aerophilous harm to proteins, enzymes and DNA shows the foremost vital external sources of free radicals⁵³.




Fig 2:- The most important external sources of free radicals caused negative influence on human organism^{54, 55}

Oxidative stress is placed collectively of the foremost necessary causes of Alzheimer's sickness. The foremost recent studies confirmed the influence of reactive chemical element species on the event of the disorders. Because of the very fact that the brain is wealthy in simply peroxidizable fatty acids, free radicals will effectively attack these molecules resulting in the formation of new, harmful structures. What is more, it absolutely was established that amyloid peptides impact on radicals.

Influence of antioxidants on Alzheimer's disease:-

A large range of reports show a job of aerobic stress in Alzheimer sickness (AD). Some recent proof even suggests that this development is associated in Nursing early event and should play a purposeful role within the pathological process of this sickness. Chronic, low-dose inhibitor medical aid is each safe and effective in lowering the accumulative harm of aerobic stress product. Before beginning any inhibitor medical aid, it's vital to possess clear info on the endogenous inhibitor levels. The foremost necessary thought is that the got to monitor the medical aid. Numerous compounds have the flexibility to quench free radicals exploitation 3 mechanisms: interference (or reduction) of the formation of free radicals, reacting with them directly or limiting the extent of the harm by detoxification. The primary cluster includes, modulators of SOD (SOD), catalase, and antioxidant, iron chelators and caloric restriction. SOD, Catalase, and antioxidant are the 3 primary enzymes concerned in direct elimination of active chemical element species whose activity is reduced with age and in some pathological conditions^{32,33}. Amyloid- beta (Ab) plays a crucial role within the pathological process of AD. The buildup of Ab stimulates vegetative cell activation, leading to increased production of a spread of aerobic and pro-inflammatory mediators, which can play a crucial role in somatic cell pathology in Alzheimer's sickness. Therefore, to soundly forestall or maybe take away the poisonous substance, Ab amide is taken into account to be an efficient technique for the interference and treatment of AD⁵⁸. Many older folks concern that they need Alzheimer's illness as a result of they can't realize their eyeglasses or keep in mind someone's name. These quite common issues area unit most frequently because of deceleration of mental processes with age. whereas it's a nuisance, it doesn't considerably impair a person's ability to be told new info, solve issues, or perform everyday activities, as Alzheimer's illness will. Memory loss follows a particular pattern in Alzheimer's illness. The losses area unit chiefly in remembering⁵⁹.

Memory functioning has been recognized follows:

- Short-term memory:-

Short-term memory is that the capability to carry little amounts of data within the brain.

Short term loss suggests that it's impaired, and also the person simply appears forgetful. It's common for the aging brain to start to lose remembering⁶⁰.

Long-term memory

Long-term memory may be a totally different sort of memory within which you hold info in your brain from the past. Memory loss may be caused by problems like injury, infection or trauma. Someone with memory loss can usually forget their past like recent friend's names or necessary vacations that they went on with their family⁶¹.

- I. **Semantic and episodic memory:** - linguistics recollections area unit context-free facts. As an example, knowing what I had for breakfast may be an episodic memory; knowing that the word 'breakfast' suggests that a morning meal is a long-term memory.
- II. **Declarative and procedural:** - Procedural memory is for skills and routines and should embody some sorts of sensory stimuli. As an example, knowing a way to drive an automobile may be a post, knowing however the engine works is declarative⁶².

STAGES OF ALZHEIMER'S DISEASE:-

It is currently believed that there area unit four stages concerned in memory: registration, encoding, Storage and retrieval. For info to be kept in memory it should 1st be attended to or Registered. Cryptography is that the

method whereby this info is also or phonologically encoded, encoded in terms of that means or sound, severally. Storage is that the method by that information is maintained in memory^{63, 64}.

Table 1: symptoms experienced by people with dementia syndrome ⁶⁴

Sr. no.	Early stage	Middle stage	Last stage
1	The first stage is usually unmarked.. Relatives and friends (and generally professionals as well) see it as “old age”, simply a traditional a part of ageing method. as a result of the onset of the malady is gradual, it's tough to take care specifically once it begins.	As the illness progresses, limitations become clearer and a lot of limiting.	is one in all nearly total dependence and inactivity. Memory disturbances square measure terribly serious and also the physical facet of the sickness becomes a lot of obvious.
2	Become forgetful, particularly relating to things that simply happened.	Become terribly forgetful, particularly of recent events and people's names.	Have problem understanding what's happening around them to acknowledge Relatives, friends and acquainted objects.
3	May have some issue with communication, like issue to find words.	Have problem comprehending time, date, place and events; could become lost reception furthermore as within the community.	Usually unaware of your time.
4	Become lost in acquainted places. Lose track of the time, as well as time of day, month, year and season.	Have increasing problem with communication (speech and comprehension)	Unable to eat while not help could have problem in swallowing.
5	Issue creating selections and handling personal finances - Have issue winding up advanced responsibilities.	Need facilitate with care (i.e. toileting, unable to measure alone safely while not considerable support.	Increasing want for motor-assisted self-care (bathing and toileting) May have bladder and intestine incontinence. Change in quality, could also be unable to run or be confined to a chair or bed.
6	Mood and behaviour could settle down active and driven and lose hobbies could show changes.	Behaviour changes could embrace wandering, recurrent questioning, business out, clinging, disturbed sleeping.	Behaviour changes, could step up and embody aggression towards career, Non-verbal agitation.

Source:- World Alzheimer's Report 2009. London, Alzheimer's illness International, 2009. Neurological Disorders: public health challenges. WHO, Geneva, 2006². Jothee swaran et al. The prognostic validity of the 10/66 psychopathy diagnosis in Madras, India: a 3-Year follow-up study of cases best-known at baseline. Alzheimer illness and Associated Disorders, 2010⁶⁵.

Epidemiology of Alzheimer's disease:-

Now days, quite thirty six 5 Million persons reside with AD, and this might Increase in 2030 to sixty five.7 million and in 2050 to one hundred fifteen.4 million. It's calculable by the globe Health Organization (WHO) that quite five hundredth of people in developing countries resides with AD and it will go up to seventieth by 2025⁶⁶.

AD may be a important public health issue within the u. s. and plenty of different countries round the World, with a big health, social, and money burden on society. A calculable five Million Americans have AD, with a replacement diagnosing being created each sixty eight sec.8 within the US, AD is that the fifth leading explanation for death among older adults, and regarding \$200 billion square measure Spent annually on direct care of people living with insanity. Worldwide, it's calculable That thirty five million folks have AD or different styles of insanity, and regarding sixty five million folks square measure expected to possess insanity by 2030 (115 million by 2050). AD may be a multi-factorial illness, with no single cause known, and several other modifiable and non-Modifiable risk factors square measure related to its development and progression. Age is that the Greatest risk issue for the event of AD. The chance of developing AD will increase exponentially with age, about doubling each five years when age sixty five. Folks with familial kinds of AD have a chromosome dominant mutation in either one among the presenilin factors seton bodys one and fourteen or within the amyloid precursorprotein (APP) gene located on chromosome twenty one. Additionally, people with Down's syndrome (trisomy 21) have AN exaggerated risk of developing early-onset AD. The biological science of isolated AD square measure a lot of complicated andless well understood. It's known that the letter of the alphabet fourallele of the apolipoprotein E (APOE) factor set onchromosome nineteen may be a risk issue for the isolated AD⁶⁷.

Neuropathology:-

AD may be a progressive neurodegenerative encephalopathy that causes a big disruption of traditional brain structure and performance. At the cellular level, AD is characterized by a progressive loss of plant tissue neurons, particularly pyramidal cells that mediate higher psychological feature functions⁶⁸. The degeneration then spreads throughout the temporal cortical area and to membrane bone areas. Because the illness progresses, degeneration are often seen within the frontal area and eventually throughout most of the remaining cerebral cortex of note is that the undeniable fact that AD causes pronounced harm to multiple parts of the neural structure⁶⁹ as well as the hippocampal formation and therefore the major fiber tracts that connect it to the cortex (fornix and cingulum), amygdala, gyrus cinguli, and neural structure. This widespread pattern of neurodegeneration, moving each structure and cerebral mantle regions, correlates closely with the array of psychological feature deficits and activity changes that AD patient's exhibit. Additionally to psychological feature impairment across multiple domains (memory, language, reasoning, executive, and visuospatial function), patients with AD show AN impaired ability to perform activities of daily living and sometimes expertise psychiatrically, emotional, and temperament disturbances. It's been theorized that the vegetative cell harm seen in AD is expounded to the deposition of abnormal proteins each among and out of doors of neurons. This square measure the Hallmark pathological lesions of AD called 'plaques and tangles.' The abnormal proteins square measure deposited within the cortex following a conventional pattern of unfold on neural pathways that mediate memory and different psychological feature functions. 'Senile plaques' square measure animate thing accumulations of amyloid macromolecule and include insoluble amyloid-beta macromolecule (Ab). Normally, cells throughout life unharness soluble Ab when cleavage of the APP – A cell surface receptor. AD involves abnormal cleavage of APP that leads to the precipitation of Ab into dense beta sheets and formation of doddery plaques. It's believed that neuroglia and astrocytes then mountain inflammatory response to clear the amyloid aggregates, and this inflammation seemingly causes destruction of adjacent neurons and their neurites (axons and dendrites)⁷⁰. Neurofibrillary tangles' (NFT) square measure living thing aggregates of abnormally hyper-phosphorylated macromolecule letter of the alphabet, that in traditional kind is a tubule helpful macromolecule and plays a task in living thing (axonal and vesicular) transport⁶⁸.

With the present Understanding several hypothesis area unit place forth for the pathological process of AD. The widely

Accepted among them area unit as follows:-


- Mitochondrial Cascade Hypothesis
- Tau Hypothesis
- Amyloid Cascade Hypothesis

1. Mitochondrial Cascade Hypothesis:-

The reduced mitochondrial operate to handle the free-radicals is taken into account the initiating step in Alzheimer's sickness.



Fig 3 :- Important Alzheimer's pathologic conditions



2. Letter Hypothesis:-

The amyloid cascade hypothesis doesn't satisfactorily justify irregular cases of Alzheimer's sickness and therefore the level of amyloid deposits doesn't correlate with the degree of psychological feature Decline. This result in the letter hypothesis that asserts that the deposition of letter and formation of neurofibrillary tangles is that the basic pathology and therefore the amyloid deposition occur secondary to that. Letter may be a tubule associated supermolecule that binds to and stabilizes the microtubules concerned in animate thing transport⁷².

3. Amyloid Cascade Hypothesis:

The deposition of A β 42 – amyloid plaques within the Brain is taken into account the essential pathology. A β 42 comes from Amyloid Precursor supermolecule (APP) by the serial action of β -secretase and γ -secretase. A β 42 is insoluble and aggregates to make plaques that cause Aerophilous injury and initiates inflammation processes leading on to vegetative cell death. There's hyper phosphorylation of letter proteins and their deposition as neurofibrillary tangles secondary to amyloid deposition. Alzheimer's sickness happens in 2 forms – familial and irregular forms. Familial forms have associate degree early onset and area unit related to mutations in APP factor (chromosome 21), Presenillin-1 (chromosome 14) and Presenillin-2 genes (chromosome 1). The late onset familial kind and irregular kinds of AD area unit related to the presence of ApoE4 gene.

Diagnosis of Alzheimer sickness

Alzheimer sickness is sometimes diagnosed on physical and neurologic exams, and checking For signs of intellectual impairment through customary tests of mental operate. For a designation of AD, new criteria were revealed in 2011⁷⁴. McKhan et al. outline the initial and most outstanding psychological feature deficits supported history and Examination in one amongst the subsequent the subsequent.

- **Amnestic presentation:** it's the foremost common syndromic presentation of AD insanity. The deficits ought to embrace impairment in learning and recall of recently learned data. There ought to additionally be proof of psychological feature pathology in a minimum of one different psychological feature domain, as outlined earlier within the text.
- **Nonamnestic presentations:** Language presentation: the foremost outstanding deficits area unit In word-finding, however deficits in different psychological feature domains ought to be gift. Visuospatial presentation: the foremost outstanding deficits area unit in special psychological feature, together with object brain disease, impaired face recognition.
- **Executive dysfunction:** the foremost distinguished deficits area unit impaired reasoning, Judgment, and downside determination. Deficits in different psychological feature domains ought to be gift. Diagnostics tests like imaging and CT and laboratory testing also are done to rule out Medical causes of diminished brain perform.

To fitly diagnose for AD, different styles of insanity or diseases got to be dominated out. This includes the following:

- **Medication-induced insanity:** Medication-induced insanity is that the most frequent reason behind “reversible” dementia. To rule out a medication-induced insanity, an intensive Drug history and a review of all current medication (both prescription and over-the-Counter) wants be undertaken.
- **Metabolic/endocrine/nutritional/systemic disorders. Metabolic/endocrine/nutritional:** general disorders (e.g., glandular disease, B12 deficiency, and general diseases and serious metal poisoning) area unit further causes of “reversible” dementias and might be diagnosed with routine laboratory tests. Tests suggested embody blood count, erythrocyte sedimentation rate (if indicated) and electrolytes (including calcium), liver and nephritic perform tests, urinalysis, syph medical science, B12 levels, and thyroid performs tests and a Toxicity screen (if case history and also the physical communication thus indicate).

▪ **Vascular dementias/hydrocephalus/tumors/hematoma:-**

Tube insanity (VaD) might Result as a sequel to any sort of vessel sickliness and blood hyper consistence. VaD is liable for just about twenty per cent of insanity cases together with Alzheimer sickliness.

▪ **Normal pressure abnormal condition, brain tumors, and meninx hematoma:** the foremost Common of the structural brain lesions, and stroke can even gift with insanity. Confirmation or exclusion of their presence typically needs a CT or imaging scan.

▪ **Depression** is another common reason behind insanity within the old population. The subsequent symptoms psychological feature impairment symptoms could also be present: confusion, Memory disturbance, and a focus deficits, all of which may be mistaken for insanity. Depression might also be with insanity and exacerbate the matter, causing; “excess incapacity.” A decent history and thorough mental- status is needed as a part of the treatment set up. The DSM-IV criterion for identification of depression is commonly brought up make sure or rule out depression. Because the patients tormented by Alzheimer sickliness area unit advanced in age they’re seemingly to own different chronic sicknesses. Most patients with chronic sicknesses don’t have one, predominant condition. Rather, most have comorbidity, the co- occurring presence of multiple chronic conditions.

The clinical criteria and identification of dementias, together with AD, has not modified since the 1990’s. Given the benefits of early identification and early intervention, there’s associate pressing got to revise the factors for identification so the sickliness could also be known within the earlier stages. There’s abundant analysis in characteristic the shift between EARLY psychological feature changes related to insanity which related to traditional aging, a vicinity called gentle psychological feature impairment (MCI). The present accord is that gentle psychological feature impairment isn’t substitutable with early insanity; one in 3 regress, one in 3 keeps constant and one in 3 attain insanity. This remains a challenge for each clinicians and researchers since the mini condition Examination (MMSE), insanity Rating Scale and different evaluating tools area unit comparatively insensitive to early psychological feature symptoms⁷⁶.

Clinical criteria for probable AD / dementia:-

1. Presence of dementedness (as per criteria in Table)
2. Gradual onset of symptoms over months to years
3. History of progressive psychological feature decline
4. Initial presentation is also cognitive state (typical) or
5. Non-amnestic (atypical) proof for one more reason for psychological feature impairment: vas malady, alternative dementedness syndromes, or Neurological/medical malady.

Table 2:- Clinical features that distinguish ad from other dementias

Sr. No.	Clinical features	Alzheimer’s dementia	Vascular demetia	Parkinson’s dementia	Dementia with Lewy bodies	Front temporal dementia
1.	Patient profile	Greater than 65 year old	More than 40 years old vascular risk factor.	Parkinson’s dementia.	75 year old (mean)	Front temporal dementia
2.	History	Gradual onset and Deterioration	Acute onset Step wise deterioration dysfunction.	More than 65 year old.	Gradual onset and	50-70 year old 50% autosomal dominant.

3.	Initial symptoms	Loss of memory.	Executive	Hallucinations	Deterioration, Hallucinations,	Gradual onset and deterioration memory intact disinhibition, apathy or aphasia.
4.	Physical findings	Less or no impairment (until late stage).	Pyramidal (upper neuron (motor) sign).	Parkinsonism Gradual onset Deterioration, visual (preceding dementia by more than 1 year)	Fluctuating attention. Parkinsonism (Within 1 year of dementia IIIa).	Usually none (associated with motor neuron disease).

Control Strategy:-

Dementia may be an advanced sickness and its management is commonly difficult. Temperament and behavioral changes, and also the ultimate inability to perform activities of daily living cause Dependence. As purposeful impairment deteriorates, health care utilization will increase till Patients area unit forced to become institutionalized. Patients will stay in severe stages of AD For many years⁷⁸. The United States of America National Institutes of Health (NIH) conducted a state-of-the-science conference review in 2010 to produce health- care suppliers, patients and also the public with associate degree assessment of presently on the market information on bar of Alzheimer sickness and psychological feature decline. Their report states that “firm conclusions cannot be drawn regarding the association of any modifiable risk issue with psychological feature Decline or Alzheimer disease”. However, the proof base remains incomplete and additional analysis is needed.

Treatment of AD:-

There is no cure for AD, and drug medical care for the sickliness continues to be in its infancy. Approved medications for the treatment of probable AD facilitate management the symptom of AD however don't curtail the progression or reverse the course of the sickliness itself⁷⁹. The therapeutic choices have centered on meliorative the symptoms in addition as reducing the speed of progression of injury, though this has not considerably reversed the sickliness, therefore bar may be a higher answer for this public ill health⁸⁰. Efforts in etiology-based treatment square measure presently afoot in clinical trials, in addition as complement preventive treatments like physical activity, correct diet, psychological feature stimulation, and also the management of comorbidity⁸¹.

- **Acetyl cholinesterase Inhibitors:-**

It is standard that neurotransmitter (Ach) plays an important role in mediating learning and memory⁸². What is more, direct interaction between A β and cholinergic systems has been planned, with feedback to the assembly of the peptide; it's been recommended that the alteration during this feedback loop and abnormal accumulation of A β reduced cholinergic transmission effectiveness, centered on alpha-7 nicotinic neurotransmitter receptors⁸³. On this basis, effective treatment for AD is achieved with enzyme inhibitors that correspond well to Davies and Maloney's early cholinergic deficit hypothesis (1976) explaining AD pathophysiology. Tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, Para-amino carboxylic acid, coumarin, flavonoid, and pyrroloisoxazole analogs are developed and studied for the treatment of AD. Rivastigmine, donepezil And galantamine square measure the approved medication that promote higher Ach levels and improve the brain's cholinergic operate by inhibiting the protein acetyl cholinesterase that degrades the neurochemical. In general, acetyl cholinesterase inhibitors (except Tacrine) square measure well tolerated and adverse effects square measure dose-related⁸⁴.

- **N-Methyl-D-aspartate Receptor (NMDA) Antagonist:-**

Glutamate-mediated excite toxicity is thought to lead to Ca overload and mitochondrial dysfunction, with enlarged gas generation, which might be prejudicious to cells, forming high levels of oxidants and eliciting somatic cell necrobiosis⁵⁵. This overstimulation is blocked by NMDA receptor antagonists like meantime, that was approved in 2003 by the Food and Drug Administration (FDA) for the treatment of moderate-to-severe AD⁸⁶. This cooperative glutamatergic NMDA receptor associate degree agonist is administered alone or together with an acetylcholinesterase⁸⁷.

- **Other neurochemical Systems:-**

Muscarinic and nicotinic Ach receptors also are thought-about targets for AD treatment, though property of the agonists has been a haul outcome in clinical trials. EVP-6124 is presently in clinical test clinical test. Amine receptors, notably H3 receptors, also are gift in giant amounts in memory- and cognition-related structures within the brain. It looks that H3 receptor antagonists could improve cholinergic neurotransmission. Clinical test and II studies with H3 antagonist's square measure presently being conducted⁸⁹.

Etiology-Based Treatment:-

As indicated on top of, ApoE ϵ 4 is that the major genetic risk issue for noncontiguous AD (the major risk issue is age), although, for disease-modifying treatment supported the amyloid cascade hypothesis, efforts are targeting enzyme modulation and amyloid binders, still as targeting kinases concerned within the hyper phosphorylation of letter of the alphabet super molecule..

1.Secretase Inhibitors:-

APP is 1st cleaved either by α -secretase or by β -secretase enzymes, and also the ensuing fragments are processed by γ -secretase. The proposal of the "over activation" of β - and γ -secretases, or age-related shriveled process, has LED to the utilization of inhibitors for this amyloid genic pathway⁹¹. Many metalloproteinase are studied with α -secretase activity. The up regulation with medicinal drug (PPAR- α agonist) of the α -secretase "A disintegrin and metalloproteinase" ten (ADAM10) has been projected as an honest strategy for the interference of A β generation; internal secretion additionally stimulates the nonamyloidogenic process of APP through positive transcriptional regulation of ADAM10 and ADAM179. And stimulation with monoamine neurotransmitter 5- HT4 receptor agonists regulates α -secretase activity⁹². Overexpression of matrix metalloproteinase nine (MMP- 9, another α -secretase) additionally prevents psychological feature deficits displayed by the transgenic AD mouse model harboring 5 familial AD-related mutations (5xFAD)⁹³.

The transmembrane aspartyl peptidase BACE1 has inhibitors projected with a molecular docking-based approach for the inaccessible chemical change center that originally LED to unsuccessful trials⁹⁴. BACE1 plays a very important role within the metabolism of myelination proteins; but, its inhibition displays less severe facet effects than alternative ADAM proteases. Few compounds have reached clinical trials, the foremost promising being Merck Sharp & Dohme's MK-8931 (Verubecestat) and Eli Lilly/Astra-Zeneca's AZD3293 (LY3314814), in part II/III trials NCT01739348 and NCT02245737, severally. Flavonols and flavones, particularly metrification and quercetin, have exhibited superb acellular BACE1 restrictive effects⁹⁵.

There are several studies with γ -secretase inhibitors that elicited important facet effects, together with disorders and exaggerated risk of carcinoma⁹⁶. Gama-secretase activity is additionally required before β -secretase reaches APP so as to stop A β , since proof for genetic defects in -secretase (PSEN-1 and PSEN-2) as major risk factors for familial AD is conclusive. This could justify why the utilization the utilization inhibitors has failing in early trials however modulators of this advanced have higher expectations.

The toxicity of γ -secretase inhibitors depends on alternative sign pathways activated by alternative cleaved receptors, together with Notch receptor. It's been shown that a γ -secretase substance, however not a γ -secretase modulator, induces defects in BDNF nerve fiber trafficking and sign. These modulators have effects on the A β cleaving web site generator while not touching alternative cleaving sites of the advanced.

2. Amyloid Binders:-

The deposition of A β in AD is concentration-dependent; exaggerated amyloidogenic process of APP and inefficient removal of peptides could also be concerned within the pathology. There's reduced activity of A β -degrading enzymes, such as neprilysin, associated degree insulin-degrading accelerator, moreover because the ApoE determinant, that correlates well with the proposal of AD as a disorder. Preventing the formation of A β amyloid plaques is one in every of the targets for disease-modifying treatment in AD, though there's proof of correlation with A β biomarkers and psychological feature deficits, previous to dementing plaques. Inhibitors of A β aggregation have reached clinical trials. However, active and passive protection could involve facet effects with neuroinflammation, that is taken into account in itself to elucidate the pathophysiology of AD, and anti-inflammatory agents for treatment of AD could be thought-about as well⁹⁹. Anti-A β Aggregation Compounds In recent decades, analysis has centered on developing therapies during which during which amide formation or its aggregation is prevented. Among the tiny molecule inhibitors of A β aggregation in clinical trials are tramiprosate (phase III), fungicide (phase II), scylloinositol (phase II), and epigallocatechin-3-gallate (phase II/III); though these medication have achieved stabilization of the A β monomers, they need necessary facet effects¹⁰⁰. Also, artificial breaker peptides of the I A β 5p sequence like azetidine-2-carboxylic acid, 3-phenyl azetidine-2-carboxylic acid, β -proline, and β -sulfonylproline modulate the cell harm caused by the A β exposure by preventing strand formation and that they have shown improved results with relation to spacial memory¹⁰¹. tau medical care Inhibitors of the phosphorylation of alphabetic character proteins like tideglusib, associated degree irreversible GSK-3 β matter, are tested with no statistically vital advantages; cyclin-dependent enzyme five (CDK5), that is additionally concerned within the hyperphosphorylation of alphabetic character proteins, has been thought-about as a doable drug target. Many molecules are shown to act pretty much as good inhibitors of alphabetic character aggregation and are in clinical trials. Among these medication, thiazine (MB) and its metabolites azure A and azure B are ready to promote macromolecule degradation and inhibit caspase-1 and caspase-3 activity. Similarly, leucomethylthionium with an acceptable (LMTX in phase III clinical trial clinical trials) and methylthionium chloride or MTC (phase II clinical trial) are shown to cut back alphabetic character aggregation and reverse activity deficits in transgenic mouse models¹⁰². and to slow the progression of the malady in patients with AD¹⁰³. Other medical care as associated degree age-related pathology, a kind three polygenic disorder hypothesis of AD has been developed, and intranasal hypoglycemic agent is enclosed as a doable treatment for the malady, thanks to its ability to penetrate the brain-blood barrier¹⁰⁴. Elevated beta-lipoprotein (LDL) concentration will increase the chance of developing AD however the employment of statins as a protecting treatment is arguable. Dyslipidemia and avoirdupois are thought-about anorectic factors in respect to alternative pathologies like metabolic syndrome, which has atherogenic dyslipidemia and central avoirdupois, symptom and hypoglycemic agent resistance, cardiovascular disease, and a prothrombotic state and a pro-inflammatory state¹⁰⁵.

Non pharmacologic Treatments:-

AD bar ways is divided into 2 teams, the primary related to manner and also the second with diet and chemical compounds.

- **Lifestyle:-**

Lifestyle ways embody physical activity, mental challenges, energy restriction, and socialization as preventive factors in AD. Physical activity like aerobics was related to the reduction of AD deficits during a cohort study. This wasn't in step with studies that thought of a little range of cases¹⁰⁷. It's been projected that mental challenges could defend against psychological feature decline and doubtless against AD. Pc courses and psycho education have moderate helpful effects. Stimulation by psychological feature activities has been related to a rise in neuronal density that provides brain reserve and physical property physical property. The relation between caloric restriction and brain motivation is very important since a few years past humans required to get their food by killing wild animals and sometimes vigorous exercise was needed.

Socialization is very important to mental and physical human development and an absence thence induces loneliness, that has been related to varied diseases like depression, habit, obesity, diabetes, cardiovascular disease, AD, and cancer¹⁰⁹.

- **Diet and Chemical Substances:-**

Dietary supplements for bar of AD were studied with vitamins like B6, B12, folates, and E, C, and D vitamins. Vitamin B studies created mixed results; on one hand, a biennial treatment with homocysteine and vitamin B in 271 patients indicated a major distinction compared to placebo in whole brain atrophy, whereas different reports indicate completely different results. It's been projected that vitamin M has neuroprotective activity through associate epigenetic mechanism that inhibits amyloid- β amide accumulation. Studies with 2000 IU of tocopherol didn't indicate a protecting result for AD with 3 years of treatment, nor with the combined treatment with water- soluble vitamin to boot, does ergocalciferol supplementation improve psychological feature performance¹¹⁰.

Another diet associated with neuroprotection against neurodegenerative diseases is that the Asiatic diet, as a result of it includes high levels of tea leaf consumption, the inhibitor curcumin, and also the dietary supplement gymnospermous tree biloba, thought of to be a guardian against memory decline, thanks to its inhibitor result and also the decrease of A β aggregation; it's necessary to extend the analysis so as to grasp its virulent effects. On the opposite hand, the western diet is taken into account as a risk issue for AD as a result of it's characterized by excessive consumption of sugar animal merchandise, with a better content of saturated fats, that negatively have an effect on psychological feature operate, A β -deposition, and aerobic stress¹¹¹.

CONCLUSION

The use of any live for the clinical assessment of dementedness, whether or not in folks with learning disabilities or within the 'normal' population carries with it limitations. Informed knowledge of those limitations permits North American nation scientific decisions that modify us to tailor our neuropsychological battery or adopt various measures. Ultimately, there is also a compromise due to these limitations; but, scientific understanding has given North American nation a more robust image of the course of dementedness than ever before. With the advancement of technology, like magnetic resonance imaging and magnetic resonance imaging, and PET and SPET scans, used in conjunction with psychological science tests administered at key time points together with follow ups, the practitioner is best placed to form a additional reliable diagnosing and prognosis than within the past. It's hope that this can conjointly enlighten service suppliers in widening access to folks with learning disabilities UN agency even have dementedness.

REFERENCE

- 1.M. Citron, Alzheimer's disease: strategies for disease modification, Nat. Rev. Drug Discov. 2010; (9): 387–398.
2. World Alzheimer Report 2009. London, Alzheimer Disease International, 2009. Neurological disorders: Public health challenges. Geneva, World Health Organization, 2006.
- 3.Otheeswaran AT, Williams JD, Prince MJ. The predictive validity of the 10/66 dementia diagnosis in Chennai, India: a 3-year follow-up study of cases identified at baseline. Alzheimer Disease and Associated Disorders, 2010, 24(3):296-302.
- 4.R. Kaddurah-Daouk, H. Zhu, S. Sharma, M. Bogdanov, S.G. Rozen, W. Matson, N.O. Oki, A.A. Motsinger-Reif, E. Churchill, Z. Lei, D. Appleby, M.A. Kling, J.Q. Trojanowski, P.M. Doraiswamy, S.E. Arnold, Alterations in metabolic pathways and Networks in Alzheimer's disease, Transl. Psychiatry 2013; (3): 244.
- 5.Z. Chen, C. Zhong, Decoding Alzheimer's disease from perturbed cerebral glucose Metabolism: implications for diagnostic and therapeutic strategies, Prog. Neurobiol. 2013;(108): 21–43.
- 6.Caspersen, N. Wang, J. Yao, A. Sosunov, X. Chen, J.W. Lustbader, H.W. Xu, D. Stern, G. McKhann, S.D. Yan, Mitochondrial abeta: a potential focal point for neuronal Metabolic dysfunction in Alzheimer's disease, FASEB J. 2005; (19): 2040–2041.
7. EC, Nation DA. Importance of treatment status in links Between type 2 diabetes and Alzheimer's disease. Diabetes Care.2019;42:972-979.
8. A. Ubereineeige nartige Erkrankung der Hirnrinde [About a Peculiar Disease of The Cerebral Cortex]. Allg Z Psychiatr 1907; 64: 146-48.
9. Alzheimer A. About a peculiar disease of the cerebral cortex. Alzheimer Dis AssocDisord 1987; 1: 3

10. Maurer K, Volk S, Gerbaldo H, Auguste D and Alzheimer's disease. *Lancet* 1997; 349(9064): 1546-9
11. Ziegler-Graham, *Alzheimer & Dementia* 2008;4:316-328
12. Alzheimer Europe. Available at <http://www.alzheimer-europe.org/?lm1=D8105B21BD2C> Last Accessed March 09, 2004.
13. K, de Leon MJ, Zetterberg H. 2006;368(9533):387–403
14. Epidemiology of Alzheimer Disease Richard Mayeux and Yaakov Stern Cold Spring Harb Perspect Med 2012;2:a006239
15. Intiaz B, Tolppanen AM, Kivipelto M and Soininen H: Future directions in Alzheimer's disease from risk factors To prevention. *Biochemical Pharmacology* 2014; 88(4):661-670.
16. Arvanitakis Z, Wilson, RS, Bienias, JL, Evans DA and Bennett DA: Diabetes mellitus and risk of Alzheimer Disease and decline in cognitive function. *Archives of Neurology* 2004; 61(5): 661-666.
17. Kalaria RN: Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. *Nutrition Reviews* 2010; 68(2): S74-S87
18. Alford S, Patel D, Perakakis N and Mantzoros CS: Obesity As a risk factor for Alzheimer's disease: weighing the Evidence. *Obesity Reviews* 2018; 19(2): 269-280.
19. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. *Free Radical Biology and Medicine* 1997; 23(1): 134-147.
20. Finkel T and Holbrook NJ: Oxidants, oxidative stress and The biology of aging. *Nature* 2000; 408(6809): 239.
21. Majdi A, Mahmoudi J, Sadigh-Eteghad S, Golzari SE, Sabermarouf B and Rey Hani-Rad S: Permissive role of Cytosolic pH acidification in neurodegeneration: a closer Look at its causes and consequences. *Journal of Neuro-Science Research* 2016; 94(10); 879-887.
22. Kang EB, Kwon IS, Koo JH, Kim EJ, Kim CH, Lee J, Yang CH, Lee YI, Cho, IH and Cho JY: Treadmill Exercise represses neuronal cell death and inflammation During A β -induced ER stress by regulating unfolded Protein response in aged presenilin 2 mutant mice. *Apoptosis* 2013; 18(11): 1332-1347.
23. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS and Scherr PA: Dietary Intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. 2002; 287(24): 3230-3237
24. El Kadmiri N, Said N, Slassi I, El-Moutawakil B and Nadifi S: Biomarkers for Alzheimer disease: Classical and Novel candidates' review. *Neuroscience* 2017; 370: 181-190.
25. M. A. Pagano, E. R. Marschoff, S. E. González, M. G. Repetto, and J. A. Serra, "Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis," *Neurologia*, vol. 29, no. 9, pp. 567–572, 2014.
26. D. K. Shoe mark and S. J. Allen, "The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer's disease," *Journal of Alzheimer's Disease*, vol. 43, no. 3, pp. 725–738, 2015.
27. C. M. Lema Tomé, T. Tyson, N. L. Rey, S. Grathwohl, M. Britschgi, and P. Brundin, "Inflammation and α -synuclein's prion-like behavior in Parkinson's disease—is there a link?" *Molecular neurobiology*, vol. 47, no. 2, pp. 561–574, 2013.
28. R. Sandhir and S. Gupta, "Molecular and biochemical trajectories from diabetes to Alzheimer's disease?: a critical appraisal," *World Journal of Diabetes*, vol. 6, no. 12, pp. 1223–1242, 2015.
29. P. G. Ridge, M. T. Ebbert, and J. S. Kauwe, "Genetics of Alzheimer's disease," *BioMed Research International*, vol. 2013, Article ID 254954, pages 13 2013.
30. Y. Gu, Q. R. Razlighi, L. B. Zahodne et al., "Brain amyloid deposition and longitudinal cognitive decline in nondemented older subjects: results from a multi- ethnic population," *PLoS ONE*, vol. 116, pp. 1–14, 2015.
31. J. B. S. Langbaum, K. Chen, R. J. Caselli et al., "Hypometabolism in Alzheimer-affected brain regions in cognitively healthy latino individuals carrying the apolipoprotein E ϵ 4 allele," *Archives of Neurology*, vol. 67, no. 4, pp. 462–468, 2010.
32. L. Xie, H. Yan, L. Shi et al., "Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population," *Neuroscience Letters*, vol. 618, pp. 77–82, 2016.
33. M.-X. Tang, G. Maestre, W.-Y. Tsai et al., "Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City," *The American Journal of Human Genetics*, vol. 58, no. 3, pp. 574–584, 1996.

34. L. Xie, H. Yan, L. Shi et al., "Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population," *Neuroscience Letters*, vol. 618, pp. 77–82, 2016.
35. Wang, L. Fratiglioni, E. J. Laukka et al., "Effects of vascular risk factors and APOE ϵ 4 on white matter integrity and cognitive decline," *Neurology*, vol. 84, no. 11, pp. 1128–1135, 2015.
36. C. M. Karch and A. M. Goate, "Alzheimer's disease risk genes and mechanisms of disease pathogenesis," *Biological Psychiatry*, vol. 77, no. 1, pp. 43–51, 2015.
37. J. R. P. Prasanthi, M. Schrage, B. Dasari et al., "Deferiprone reduces amyloid- β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet," *Journal of Alzheimer's Disease*, vol. 30, no. 1, pp. 167–182, 2012.
38. W. L. F. Lim, I. J. Martins, and R. N. Martins, "The involvement of lipids in Alzheimer's disease," *Journal of Genetics and Genomics*, vol. 41, no. 5, pp. 261–274, 2014.
39. L. K. Cuddy, W. Winick-Ng, and R. J. Rylett, "Regulation of the high-affinity choline transporter activity and trafficking by its association with cholesterol-rich lipid rafts," *Journal of Neurochemistry*, vol. 128, no. 5, pp. 725–740, 2014.
40. E. Kojro, G. Gimp, S. Lammich, W. Marz, and F. Fahrenholz, "Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α -secretase ADAM 10," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 10, pp. 5815–5820, 2001.
41. J. Poirier, J. Miron, C. Picard et al. "Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease," *Neurobiology of Aging*, vol. 35, no. 2, pp. S3–S10, 2014.
42. G. Marwarha and O. Ghribi, "Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease—Parkinson's disease overlap?" *Experimental Gerontology*, vol. 68, pp. 13–18, 2015.
43. M. Han, Y. Liu, Q. Tan et al., "Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease," *European Journal of Pharmacology*, vol. 657, no. 1–3, pp. 104–110, 2011.
44. R. Poddar and S. Paul, "Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death," *Journal of Neurochemistry*, vol. 110, no. 3, pp. 1095–1106, 2009.
45. J. H. Birnbaum, J. Bali, L. Rajendran, R. M. Nitsch, and C. Tackenberg, "Calcium flux-independent NMDA receptor activity is required for A β oligomer-induced synaptic loss," *Cell Death & Disease*, vol. 6, no. 6, Article ID e1791, 2015.
46. M. Weizmann, C. Capone, V. Zerbi et al., "Hypertension impairs cerebral blood flow in a mouse model for Alzheimer's disease," *Current Alzheimer Research*, vol. 12, no. 10, pp. 914–922, 2015.
47. E. Joas, K. Backman, D. Gustafson et al., "Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years," *Hypertension*, vol. 59, no. 4, pp. 796–801, 2012.
48. A. Christensen and C. J. Pike, "Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease," *Frontiers in Aging Neuroscience*, vol. 7, article 130, pp. 1–14, 2015.
49. V. A. Moser and C. J. Pike, "Obesity and sex interact in the regulation of Alzheimer's disease," *Neuroscience & Biobehavioral Reviews*, 2015.
50. D. Petrov, I. Pedro's, G. Artiach et al., "High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiencies contribute to Alzheimer disease pathology in rodents," *Biochimica et Biophysica Acta—Molecular Basis of Disease*, vol. 1852, no. 9, pp. 1687–1699, 2015.
51. V. Sivanandham, Free radicals in health and diseases—a mini review, *Pharmacologyonline 1* (2011) 1062–1077.
52. V.I. Lushchak, Free radicals, reactive oxygen species, oxidative stress and its Classification, *Chem.-Biol. Interact.* 224 (2014) 164–175.
53. S.P. Faux, T. Tai, D. Thorne, Y. Xu, D. Breheny, M. Gaca, The role of oxidative Stress in the biological responses of lung epithelial cells to cigarette smoke, *Biomarkers* 14 (2009) 90–96.
54. A. Das Sarma, A.R. Malik, A.K. Ghosh, Free radicals and their role in different Clinical conditions: an overview, *IJPSR* 3 (2010) 185–192.
55. Reference Early Review on dementia by Christopher Melinosky, MD on October 29, 2020 WebMD.com
56. M. Gubandru, D. Margina, C. Tsitsimpikou, N. Goutzourelas, K. Tsarouhas, Miillie, A.M. Tsatsakis, D. Kouretas, Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers, *Food Chem. Toxicol.* 61 (2013) 209–214.
57. S.L. Siedlak, G. Casadeus, K.M. Webber, M.A. Pappolla, C.S. Atwood, M.A. Smith, G. Perry, Chronic antioxidant therapy reduces oxidative stress in a Mouse model of Alzheimer's disease, *Free Radic. Res.* 43 (2009)

156–164.

58. H.R. Andersen, B. Jeune, J.B. Nybo, K. Andersen-Ranberg, P. Grandjean, Low activity of superoxide dismutase and high activity of glutathione reductase in erythrocytes from centenarians, *Age Ageing* 27 (1998) 634.
59. Q. Liu, F. Xie, R. Rolston, P.I. Moreira, A. Nunomura, X. Zhu, M.A. Smith, G.Perry, Prevention and treatment of Alzheimer Disease and aging:Antioxidants, *Mini-Rev. Med. Chem.* 7 (2007) 171.
60. D. Pratico, Evidence of oxidative stress in Alzheimer's Disease brain and Antioxidant therapy, *Ann. N.Y. Acad. Sci.* 1147 (2008) 70–78.
61. <https://www.livescience.com/42891-short-term-memory-loss.html>.
62. Chandrashekar K, Vinayak M, Saritha MK. Recent advances in the management of Alzheimer's disease, *Int J Pharm Bio Sci* 2013; 4(3): 519-523.
63. <https://www.webmd.com/brain/memory-loss>
64. Morris, R.G. 'Recent developments in the neuropsychology of dementia', *International Review of Psychiatry.* 1994b; 6: 85-107.
65. APA – American Psychiatric Association. 'Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed', Washington DC: American Psychiatric Association. 1994;139-143.
66. Greene, J.D.W., Hodges, J.R. &Baddeley, A.D. (1995), 'Autobiographical memory and Executive function in early dementia of Alzheimer type', *Neuropsychologia.* 1995;33(12): 1647-1670
67. Worlde AR, Chandra S, Diwan A and Harke SA: Alzheimer's and current therapeutics: A review. *Asian J Pharm Clin Res* 2015; 8(3): 14-19.
68. WHO dementia report. World Health Organization.
69. World Alzheimer Report 2009. London, Alzheimer Disease International, 2009. Neurological disorders: public health challenges. Geneva, World Health Organization, 2006.
70. Mann DM. Pyramidal nerve cell loss in Alzheimer's disease. *Neurodegeneration* 1996; 5: 423-7.
71. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second century. *Sci Transl Med* 2011;3: 77sr1. Doi:10.1126/scitranslmed.3002369
72. Norfray JF, Provenzale JM. Alzheimer's disease: neuropathology findings and recent advances in imaging. *AJR Am J Roentgenol* 2004; 182: 3-13. Doi: 10.2214/ajr.182.1.1820003.
73. Braak H, Thal DR, Ghebremedhin E, Del Triadic K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathology Exp Neurol* 2011; 70: 960-9. Doi: 10.1097/NEN.0b013e318232a379.
74. Chandrashekar K, Vinayak M, Saritha MK. Recent advances in the management of Alzheimer's disease, *Int J Pharm Bio Sci* 2013; 4(3): 519-523.
75. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid β peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. *J Psychiatry Neurosci.* 2013 Jan;38(1):6-23.
76. Alzheimer Europe. Available at <http://www.alzheimer-europe.org/?lm1=D8105B21BD2C> Last Accessed March 09, 2004.
77. Richard Mayeux and Yaakov Stern. Epidemiology of Alzheimer Disease. *Cold Spring Harb Perspect Med* 2012;2:a006239
78. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National institute on Aging-Alzheimer's Association workgroups on Diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; 7(3): 263-9. Doi: 10.1016/j.jalz.2011.03.005
79. Drug Treatment in Dementia. Fact Sheet 8. Updated April 2000. Last accessed March 09, 2004. Alzheimer's Disease International. <http://www.alz.co.uk/adi/publications.html#factseets>.
80. Daviglus ML et al. Risk factors and preventive interventions for Alzheimer disease: state of the Science. *Archives of Neurology*, 2011, 68(9):1185-1190.
81. A. Kumar, C. M. Nisha, C. Silakari Nisha et al., "Current and novel therapeutic molecules and targets in Alzheimer's disease," *Journal of the Formosan Medical Association*, vol. 115, no. 1, pp. 3–10, 2016.
82. L. Nelson and N. Tabet, "Slowing the progression of Alzheimer's disease; what works?" *Ageing Research Reviews*, vol. 23, pp. 193–209, 2015.
83. C. Van Cauwenberghe, C. Van Broeckhoven, and K. Sleegers, "The genetic landscape of Alzheimer disease: clinical implications and perspectives," *Genetics in Medicine*, vol. 18, no. 5, pp. 421–430, 2015.

84. D. Puzzo, W. Gulisano, O. Arancio, and A. Palmeri, "The keystone of Alzheimer pathogenesis might be sought in A β physiology," *Neuroscience*, vol. 307, pp. 26–36, 2015.
85. P. Anand and B. Singh, "A review on cholinesterase inhibitors for Alzheimer's disease," *Archives of Pharmaceutical Research*, vol. 36, no. 4, pp. 375–399, 2013.
86. J. Folch, D. Petrov, M. Ettcheto et al., "Current research therapeutic strategies for Alzheimer's disease treatment," *Neural Plasticity*, vol. 2016, Article ID 8501693, 15 pages, 2016.
87. X. Shi, X. Lin, R. Hu, N. Sun, J. Hao, and C. Gao, "Toxicological differences between NMDA receptor antagonists and cholinesterase inhibitors," *American Journal of Alzheimer's Disease and Other Dementias*, vol. 31, no. 5, pp. 405–412, 2016.
88. M. Dhar, G. A. Wayman, M. Zhu, T. J. Lambert, M. A. Davare, and S. M. Appleyard, "Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade in the hippocampus," *The Journal of Neuroscience*, vol. 34, no. 30, pp. 10022–10033, 2014.
89. A. Kumar, C. M. Nisha, C. Silakari et al., "Current and novel therapeutic molecules and targets in Alzheimer's disease," *Journal of the Formosan Medical Association*, vol. 115, no. 1, pp. 3–10, 2016.
90. J. Godyń, J. Jończyk, D. Panek, and B. Malawska, "Therapeutic strategies for Alzheimer's disease in clinical trials," *Pharmacological Reports*, vol. 68, no. 1, pp. 127–138, 2016.
91. J. Folch, D. Petrov, M. Ettcheto et al., "Current research therapeutic strategies for Alzheimer's disease treatment," *Neural Plasticity*, vol. 2016, Article ID 8501693, 15 pages, 2016.
92. M. Chen, "The maze of APP processing in Alzheimer's disease: where did we go wrong in reasoning?" *Frontiers in Cellular Neuroscience*, vol. 9, article 186, pp. 1–10, 2015.
93. A. A. Pimenova, A. Thathiah, B. De Strooper, and I. Tesseur, "Regulation of amyloid precursor protein processing by serotonin signaling," *PLoS ONE*, vol. 9, no. 1, Article ID e87014, 2014.
94. A. Fragkouli, E. C. Tsilibary, and A. K. Tzinia, "Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice," *Neurobiology of Disease*, vol. 70, pp. 179–189, 2014.
95. J. Folch, D. Petrov, M. Ettcheto et al., "Current research therapeutic strategies for Alzheimer's disease treatment," *Neural Plasticity*, vol. 2016, Article ID 8501693, 15 pages, 2016.
96. A. Kumar, C. M. Nisha, C. Silakari et al., "Current and novel therapeutic molecules and targets in Alzheimer's disease," *Journal of the Formosan Medical Association*, vol. 115, no. 1, pp. 3–10, 2016.
97. J. Godyń, J. Jończyk, D. Panek, and B. Malawska, "Therapeutic strategies for Alzheimer's disease in clinical trials," *Pharmacological Reports*, vol. 68, no. 1, pp. 127–138, 2016.
98. A. M. Weissmiller, O. Natera-Naranjo, S. M. Reyna et al., "A γ -secretase inhibitor, but not a γ -secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP," *PLoS ONE*, vol. 10, no. 2, Article ID e0118379, 2015.
99. K. Takeo, S. Tanimura, T. Shinoda et al., "Allosteric regulation of γ -secretase activity by a phenylimidazole-type γ -secretase modulator," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 29, pp. 10544–10549, 2014.
100. M. Awasthi, S. Singh, V. P. Pandey, and U. N. Dwivedi, "Alzheimer's disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products," *Journal of the Neurological Sciences*, vol. 361, pp. 256–271, 2016.
101. A. Francioso, P. Punzi, A. Boffi et al., " β -Sheet interfering molecules acting against β -amyloid aggregation and fibrillogenesis," *Bioorganic and Medicinal Chemistry*, vol. 23, no. 8, pp. 1671–1683, 2015.
102. V. Melis, M. Magbagbeolu, J. E. Rickard et al., "Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse naturopathy models," *Behavioural Pharmacology*, vol. 26, no. 4, pp. 353–368, 2015.
103. B. Bulic, M. Pickhardt, E.-M. Mandelkow, and E. Mandelkow, "Tau protein and tau aggregation inhibitors," *Neuropharmacology*, vol. 59, no. 4-5, pp. 276–289, 2010.
104. J. Godyń, J. Jończyk, D. Panek, and B. Malawska, "Therapeutic strategies for Alzheimer's disease in clinical trials," *Pharmacological Reports*, vol. 68, no. 1, pp. 127–138, 2016.
105. K. Fukui, H. A. Ferris, and C. R. Kahn, "Effect of cholesterol reduction on receptor signaling in neurons," *The Journal of Biological Chemistry*, vol. 290, no. 44, pp. 26383–26392, 2015.
106. V. Rani, G. Deep, R. K. Singh, K. Palle, and U. C. S. Yadav, "Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies," *Life Sciences*, vol. 148, no. 11, pp. 183–193, 2016.
107. J. Verghese, R. B. Lipton, M. J. Katz et al., "Leisure activities and the risk of dementia in the elderly," *The New England Journal of Medicine*, vol. 348, no. 25, pp. 2508–2516, 2003.

108. J. A. García-Casal, A. Loizeau, E. Csipke, M. Franco-Martín, M. V. Perea-Bartolomé, and M. Orrell, "Computer-based cognitive interventions for people living with dementia: a systematic literature review and meta-analysis," *Aging & Mental Health*, 2016.
109. S. Shoib, T. Shah, and S. Mushtaq, "Relationship between loneliness, psychiatric disorders and physical health ? A review on the psychological aspects of loneliness," *Journal of Clinical and Diagnostic Research*, vol. 8, no. 9, pp. WE01–WE04, 2014.
110. A. K. Gangwar, A. Rawat, S. Tiwari, S. C. Tiwari, J. Narayan, and S. Tiwari, "Role of Vitamin-D in the prevention and treatment of Alzheimer's disease," *Indian Journal of Physiology and Pharmacology*, vol. 59, no. 1, pp. 94–99, 2015.
111. N. Hu, J.-T. Yu, L. Tan, Y.-L. Wang, L. Sun, and L. Tan, "Nutrition and the risk of Alzheimer's disease," *BioMed Research International*, vol. 2013, Article ID 524820, 12 pages, 2013

